- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Mo | DIAGONAL BIO AB: Nomination Committee appointed for Diagonal Bio | 1 | Cision News | ||
| 13.11. | DIAGONAL BIO AB: Diagonal Bio announces pilot test with LAMPlify® at Kolgjini Stables | 1 | Cision News | ||
| 11.11. | Nasdaq Stockholm AB: Diagonal Bio AB receives observation status | 134 | GlobeNewswire | Today, on November 11, 2024, Diagonal Bio AB (the "Company") disclosed a press
release with information on the Company's financial situation.
The rules of Nasdaq First North Growth Market state that... ► Artikel lesen | |
| 11.11. | DIAGONAL BIO AB: Diagonal Bio announces that it is exploring financing options | 3 | Cision News | ||
| 31.10. | DIAGONAL BIO AB: Diagonal announces first pilot test at a stud with LAMPlify® | 4 | Cision News | ||
| 25.10. | DIAGONAL BIO AB: Diagonal Bio announces pilot test of LAMPlify® at Norwegian University of Life Sciences | 5 | Cision News | ||
| 22.10. | DIAGONAL BIO AB: Diagonal Bio will present LAMPlify® at a partnered event for trainers at Jägersro | 1 | Cision News | ||
| 11.10. | DIAGONAL BIO AB: Diagonal Bio announces successful external validation of LAMPlify® for viruses in pigs | 1 | Cision News | ||
| DIAGONAL BIO Aktie jetzt für 0€ handeln | |||||
| 08.10. | DIAGONAL BIO AB: Hunneberga Horse Stable to conduct pilot test of LAMPlify® | 2 | Cision News | ||
| 03.10. | DIAGONAL BIO AB: Horse trainer Daniel Redén at StallZet will conduct a pilot with LAMPlify® | 1 | Cision News | ||
| 02.10. | Diagonal Bio AB's warrant exercise registered at the Swedish Companies Registration Office | 2 | Cision News | ||
| 27.09. | Diagonal Bio AB announces the outcome of the exercise of warrants of series TO 1 | 1 | Cision News | ||
| 19.09. | DIAGONAL BIO AB: The last day of trading in warrants of series TO 1 is on the 24th of September 2024 | 2 | Cision News | ||
| 12.09. | DIAGONAL BIO AB: The exercise period for warrants of series TO 1 commences today | 1 | Cision News | ||
| 11.09. | DIAGONAL BIO AB: The exercise price for warrants of series TO 1 has been set to SEK 0,05 per new share | 1 | Cision News | ||
| 06.09. | DIAGONAL BIO AB: Diagonal Bio announces successful external validation of LAMPlify® for respiratory viruses in horses | 1 | Cision News | ||
| 21.08. | DIAGONAL BIO AB: Diagonal Bio receives order from the Technical University of Denmark | 2 | Cision News | ||
| 11.06. | Bulletin from the Annual General Meeting on 11 June 2024 in Diagonal Bio AB | 1 | Cision News | ||
| 31.05. | Diagonal Bio AB first quarter (Q1 2024) | 2 | Cision News | ||
| 16.05. | Nasdaq Stockholm AB: New equity right for trading, Diagonal Bio AB TO1 | 214 | GlobeNewswire | At the request of Diagonal Bio AB, Diagonal Bio AB equity rights will be traded
on First North Growth Market as from May 17, 2024.
Security name: Diagonal Bio AB TO1
-----------------------------------
Short... ► Artikel lesen |
Seite:
1 2 Weiter >>
28 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| INTELLIA THERAPEUTICS | 12,555 | +0,88 % | Gen-Schere Hoffnungsträger Intellia Therapeutics: Aktie mit Kurssprung - die Hintergründe | Das Gros der Biotech- und Pharmawerte hat in den vergangenen Tagen nach der Ankündigung Donald Trumps, Robert F. Kennedy Jr. als Gesundheitsminister für die künftige Regierung nominieren zu wollen,... ► Artikel lesen | |
| PACIFIC BIOSCIENCES OF CALIFORNIA | 1,633 | +0,33 % | Pacific Biosciences Of California, Inc. Q3 Loss Decreases, Beats Estimates | WASHINGTON (dpa-AFX) - Pacific Biosciences of California, Inc. (PACB) reported Loss for third quarter that decreased from the same period last year and beat the Street estimates.The company's... ► Artikel lesen | |
| CENTOGENE | 0,070 | -1,41 % | Centogene NV: CENTOGENE Signs Strategic Transaction With Private Equity Group Charme Capital Partners | CAMBRIDGE, Mass. and ROSTOCK, Germany and BERLIN, Nov. 13, 2024 (GLOBE NEWSWIRE) -- Centogene N.V. (OTC: CNTGF) ("CENTOGENE" or the "Company"), the essential life science partner for data-driven answers... ► Artikel lesen | |
| ATAI LIFE SCIENCES | 1,552 | +3,16 % | Psychedelic drug developer Atai rises as RFK Jr picked for top US health agency role | ||
| BIOMERIEUX | 98,15 | +0,20 % | QVance AB Announces Nordic Partnership with bioMérieux | ||
| CYCLACEL | 0,345 | -2,27 % | Cyclacel Pharmaceuticals Announces Closing of Exercise of Warrants for $2.1 Million Gross Proceeds | ||
| SYROS PHARMACEUTICALS | 0,250 | -7,41 % | Syros Pharmaceuticals CEO Chee Conley verkauft Aktien im Wert von 26.932 US-Dollar | ||
| ANAPTYSBIO | 19,100 | -1,04 % | AnaptysBio, Inc.: Anaptys Announces Third Quarter 2024 Financial Results and Provides Business Update | Top-line Phase 2b data anticipated for ANB032, our BTLA agonist, in atopic dermatitis (AD) in December 2024Top-line Phase 2b data anticipated for rosnilimab, our PD-1 agonist, in rheumatoid arthritis... ► Artikel lesen | |
| XTL BIOPHARMACEUTICALS | 1,630 | 0,00 % | XTL BIOPHARMACEUTICALS LTD - 6-K, Report of foreign issuer | ||
| GENUS | 20,200 | 0,00 % | Genus Plc Expects FY25 Group Adj Profit Before Tax To Be In-line With Market View | LONDON (dpa-AFX) - Global animal genetics company Genus (GNS.L), on Tuesday, issued a trading update for the four months ending 31 October 2024 and said the Board expects Group adjusted profit... ► Artikel lesen | |
| ABIONYX PHARMA | 1,218 | -2,56 % | ABIONYX Pharma Provides an Update on Its Business and Cash Position for the Third Quarter of 2024 | Consolidated revenue of €3.4m at the end of September 2024 Cash position of €4.1m before receipt of IRIS Pharma's CIR (€610k) as of September 30, 2024 Live broadcast of the General... ► Artikel lesen | |
| MEIRAGTX | 5,550 | 0,00 % | MeiraGTx Announces $50 Million Offering of Ordinary Shares led by Sanofi and Reports Second Quarter 2024 Financial and Operational Results | - Positive data from the Phase 1 AQUAx study in radiation-induced xerostomia (RIX) presented at the American Academy of Oral Medicine 2024 annual meeting (AAOM) showed meaningful improvements in patient-reported... ► Artikel lesen | |
| METABOLIC EXPLORER | 0,000 | 0,00 % | XFRA DELETION OF INSTRUMENTS FROM BOERSE FRANKFURT - 09.10.2024 | The following instruments on Boerse Frankfurt do have their last trading day on 09.10.2024Die folgenden Instrumente in Boerse Frankfurt haben ihren letzten Handelstag am 09.10.2024ISIN NameAU0000064966 VIRG.MON.... ► Artikel lesen | |
| AKESO | 8,400 | 0,00 % | Akeso, Inc.: Akeso Announces First Patient Enrollment in Phase 3 Trial of Ivonescimab Combination as First-Line Therapy for Biliary Tract Tumors, Compared to Durvalumab | HONG KONG, Oct. 31, 2024 /PRNewswire/ -- Akeso Biopharma (9926.HK) is pleased to announce the successful enrollment of the first patient in the HARMONi-GI-01/AK112-309... ► Artikel lesen | |
| ISOFOL MEDICAL | 0,268 | 0,00 % | Isofol Medical AB: Isofol Medical AB (publ) publishes interim report, January-September 2024 | GOTHENBURG, Sweden, November 12, 2024 - Isofol Medical AB (publ), (Nasdaq Stockholm: ISOFOL), announced today that the company's interim report for January-September 2024 is now available, in Swedish... ► Artikel lesen |
Das Unternehmen DIAGONAL BIO AB kann der Branche Biotechnologie zugeordnet werden. Die relative Kursveränderung beträgt aktuell 0,00 % bei einem Aktienkurs von 0,003 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu DIAGONAL BIO AB finden Sie auf Wallstreet Online.
